资源描述
Conceptual Framework for the Metabolic Syndrome Environmental causes are responsible for the epidemic of the metabolic syndrome (NCEP)Treatment: reduce obesity and increase activity Insulin resistance is the underlying cause of the metabolic syndrome (WHO)Treatment: a) reduce obesity and increase activity b) insulin sensitizers Inflammation is the underlying cause of the metabolic syndromeTreatment: a) reduce obesity and increase activity b) insulin sensitizers c) statins, ACE Inhibitors, ARBs第1页/共30页Metabolic Syndrome Increases Risk for CHD and Type 2 DiabetesExpert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 2001;285:2486-2497.第2页/共30页The Metabolic Syndrome:Historical PerspectiveReaven G. Diabetes. 1988;37:1565-1607. HDL-CHypertension第3页/共30页The Metabolic Syndrome:Current PerspectiveAdapted from Reaven G. Drugs. 1999;58 (suppl):19-20HemodynamicNovel RiskFactors第4页/共30页ATP III: The Metabolic Syndrome*Diagnosis is established when 3 of these risk factors are present* The Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001;285:2486-2497.*The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160-3167, 2003Risk FactorDefining LevelAbdominal obesity(Waist circumference) Men102 cm (40 in) Women88 cm (35 in)TG150 mg/dLHDL-C Men40 mg/dL Women130/85 mm HgFasting glucose110 (100)*mg/dL* 2003 New ADA IFG criteria (Expert Panel,Diabetes Care 26:3160-3167, 2003)第5页/共30页WHO Metabolic Syndrome Definition 1999:Based on Clinical Criteria Insulin resistance (type 2 diabetes, IFG, IGT)* Plus any 2 of the following: Elevated BP (140/90 or drug Rx) Plasma TG 150 mg/dl HDL 35 mg/dl (men); 30 and/or W/H 0.9 (men), 0.85 (women) Urinary albumin 20 mg/min; Alb/Cr 30 mg/gWHO. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Geneva: WHO, 1999.* Note that 1999 WHO uses hyperinsulinemic euglycemic clamp whereas 1998 WHO and EGIR use HOMA-IR.第6页/共30页IRS: AACE Criteria第7页/共30页IRS: AACE Criteria Risks (Choose 1) BMI 25 kg/m2 Waist circumference Men 40” Women 35” Sedentary Lifestyle Age 40 Non-Caucasian ethnicity Family History of DM, HTM, or CVD History of glucose intolerance or gestational diabetes Personal Dx of HTN, TGL, low HDL or CVD Acanthosis nigricans Polycystic ovarian syndrome (PCOS) Nonalcoholic fatty liver disease (NAFLD) Cancer (obesity related)第8页/共30页IRS: AACE Criteria Parameters (Choose 2) Triglycerides 150 mg/dl HDL cholesterol Men 40 mg/dl Women 135/85 Blood glucose 2-hour 140 mg/dl, OR Fasting 110 125 mg/dl第9页/共30页4049Age, years2029505970Ford ES et al. JAMA 2002;287:356-359.Prevalence, %MenWomenPrevalence of the NCEP Metabolic Syndrome: NHANES III by Age第10页/共30页Ford ES et al. JAMA 2002;287:356-359.WhiteAfrican American25%Prevalence of the NCEP Metabolic Syndrome: NHANES III by Sex and Race/EthnicityMenWomen16%28%Mexican AmericanOther21%23%26%36%20%第11页/共30页DM(n=1,430)NGT(n=1,808)IFG/IGT(n=685)All(n=3,928)Isomaa B et al. Diabetes Care. 2001;24:683-689.Prevalence of CHD (%)YesNoP=.04Botnia StudyPrevalence of CHD in Patients with the Metabolic Syndrome9.2%Metabolic Syndrome4.1%11.0%5.3%27.1%P=.06P.00113.5%21.4%P.0015.5%第12页/共30页Cardiovascular Disease Mortality Increased in the Metabolic Syndrome: Kuopio Ischemic Heart Disease Risk Factor StudyLakka HM et al. JAMA 2002;288:2709-2716.Cumulative Hazard, %026812Follow-up, yearMetabolic Syndrome:Cardiovascular Disease MortalityRR (95% CI), 3.55 (1.986.43)410第13页/共30页Prevalence of CHD by the Metabolic Syndrome and Diabetes in the NHANES Population Age 50+CHD Prevalence% of Population =No MS/No DM54.2%MS/No DM28.7%DM/No MS2.3%DM/MS14.8%8.7%13.9%7.5%19.2%Alexander CM et al. Diabetes 2003;52:1210-1214.第14页/共30页NCEP vs WHO Metabolic Syndrome in Relationship to CVD Mortality: San Antonio Heart Study n = 2,815 (age 25-64) Both NCEP and WHO metabolic syndrome, 509 NCEP alone, n=197 WHO alone, n=199 12.7 year follow-up (229 deaths) Three populations considered Overall population No CVD at baseline No CVD or diabetes at baseline (primary prevention)Hunt, K (Circulation, 2004; 110:1245-1251)第15页/共30页Hazard Ratio for CVD Mortality (SAHS): Adjusted for Age, Sex and EthnicityHunt, K (Circulation, 2004; 110:1245-1251)Baseline StatusNCEPWHOGeneral Population2.53 (1.74, 3.67)1.63 (1.13, 2.36)No CVD2.71 (1.74, 4.20)1.63 (1.06, 2.52)No CVD or DM2.01 (1.13, 3.57)0.74 (0.37, 1.48)第16页/共30页Hazard Ratio for CVD Mortality (SAHS): Adjusted for Age and Ethnicity 1: No CVD at BaselineHunt, K (Circulation, 2004; 110:1245-1251)WomenMenNCEP3.93 (1.83, 8.28)1.81 (0.72, 1.57)WHO2.70 (1.36, 5.37)1.15 (0.65, 2.06)第17页/共30页Hazard Ratio for CVD Mortality (SAHS): Adjusted for Age and Ethnicity 1: No CVD at BaselineHunt, K (Circulation, 2004; 110:1245-1251)Baseline StatusWomenMen1. No DM, No NCEP MS1.001.002. No DM, Yes NCEP MS2.07 (0.72, 6.00)1.96 (0.99, 3.88)3. Yes DM, No NCEP MS3.53 (0.75, 16.7)2.34 (0.70, 7.82)4. Yes DM, Yes NCEP MS8.19 (3.51, 19.1)3.09 (1.49, 6.43)第18页/共30页Different Components of the NCEP Metabolic Syndrome Predict CHD: NHANESVariableOddsRatioLower 95%LimitUpper 95%LimitWaist circumference1.130.851.51Triglycerides1.120.711.77HDL cholesterol*1.741.182.58Blood pressure*1.871.372.56Impaired fasting glucose0.960.601.54Diabetes*1.551.072.25Metabolic syndrome0.940.541.68*Significant predictors of prevalent CHDCopyright 2003 American Diabetes AssociationFrom Diabetes, Vol. 52, 2003; 1210-1214Reprinted with permission from The American Diabetes Association.第19页/共30页Incident Diabetes after Stratification by Age or BMI, IGT, and the Metabolic SyndromeRef. Lorenzo et al, Diabetes Care, 2003, 26: 3153-3159 NCEPdefinition%YesNoNoYesIGT第20页/共30页BMI per kg/m2HDL-C per mg/dl decreaseSBP per mm HgFPG per mg/dlDifferent Components of the NCEP Metabolic Syndrome Predict Diabetes: San Antonio Heart StudyStern MP et al. Ann Intern Med 2002;136:575-581.第21页/共30页Comparison of NCEP and 1999 WHO Metabolic Syndrome to Identify Insulin-Resistant Subjects: IRAS% in Lowest Quartile of SiHanley AJ et al. Diabetes 2003;52:2740-2747.OverallHispanicsNon-Hispanic whitesAfrican AmericansNeitherNCEP OnlyWHO OnlyBoth第22页/共30页Treatment of the Metabolic Syndrome in Overweight or Obese PatientsWeight loss induced by diet and increased physical activity is the cornerstone of therapy Weight loss induced by drug therapy can also improve specific features of the metabolic syndromeBariatric surgery is the most effective weight loss therapy for extremely obese subjects and improves all features of the metabolic syndrome第23页/共30页Treatment of Metabolic Syndrome in Patients with Diabetes80-85% of diabetic subjects in North America and Europe have the metabolic syndromeHowever, most subjects with the metabolic syndrome do not have diabetesStatin therapy (4S, HPS, CARE, CARDS) is effective in diabetic subjectsBlood pressure therapy is (UKPDS, SYST-Euro, HOT) is effective in diabetic subjects第24页/共30页Treatment of Specific Clinical Features of the Metabolic SyndromeNo randomized clinical trials on hypertension therapy have presented subgroup analysis on non-diabetic subjects with the metabolic syndromeLipid therapy in the metabolic syndromeStatin therapy, positive 4S (Pyorala, Diabetes Care, 2004)Statin therapy not significant in other statin trials (HPS, ASCOT, WOSCOPS) but no evidence of heterogeneityNone of these studies used contemporary definitions第25页/共30页NCEP White Paper Introduces concept of very high risk patients with optional LDL-C goal 200 mg/dl plus non-HDL-C 130 mg/dl with low HDL-C 40 mg/dl)Acute coronary syndromeGrundy et al, Circulation, 2004; 110: 227-239.第26页/共30页Approaches to Therapy: Metabolic Syndrome Weight loss induced by behavioral therapy (weight loss and increased activity), selected pharmacotherapy, and bariatric surgery Treat existing risk factorsa) Should management be intensified over and above global risk?b) Yes, but probably not CHD risk equivalentUse of insulin sensitizing therapies in nondiabetic subjects with MSa) No for metabolic syndrome alone (no clinical trials)b) Do OGTT three outcomes: 1) DM (treat) 2) IGT 3) NGT (no treatment)c) Perhaps for IGT subjects (clinical trials available DPP, STOP-NIDDM, TRIPOD)第27页/共30页Summary: Metabolic Syndrome The metabolic syndrome predicts the development of both diabetes and CHD Insulin resistance and obesity characterize most individuals with the metabolic syndrome, although insulin resistance and obesity are not required features of the NCEP metabolic syndrome Initial therapy for the metabolic syndrome should consist of caloric restriction and increased physical activity Conventional cardiovascular risk factors such as lipids and blood pressure should be treated in individuals with the metabolic syndrome, although no national recommendations have so far suggested intensification of risk factor management No consensus exists on whether insulin sensitizers should be used in nondiabetic individuals with the metabolic syndrome第28页/共30页第29页/共30页感谢您的观看！第30页/共30页
展开阅读全文